16:09 EST Nektar (NKTR) files automatic mixed securities shelf
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar Therapeutics Reveals Promising Phase 2b Trial Results
- Nektar presents new data from REZOLVE-AD study of ACAAI
- Nektar Therapeutics’ Earnings Call Highlights Robust Growth and Innovation
- Nektar Therapeutics Reports Q3 2025 Financial Results
- Hold Rating on Nektar Therapeutics Amid Uncertainties in Rezpeg’s Clinical Trials and Market Potential